OptimizeRx Co. (NASDAQ:OPRX) Receives Consensus Rating of “Moderate Buy” from Analysts

OptimizeRx Co. (NASDAQ:OPRX) has been given an average rating of “Moderate Buy” by the seven analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $15.86.

A number of analysts recently issued reports on the stock. Stifel Nicolaus reissued a “buy” rating and set a $13.00 target price on shares of OptimizeRx in a research report on Monday, April 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 target price on shares of OptimizeRx in a research note on Monday, April 1st. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $15.00 price target on shares of OptimizeRx in a research report on Tuesday, April 16th.

OptimizeRx Price Performance

Shares of OPRX opened at $10.62 on Tuesday. OptimizeRx has a fifty-two week low of $6.92 and a fifty-two week high of $16.65. The company’s fifty day moving average is $12.11 and its two-hundred day moving average is $12.16. The firm has a market cap of $193.07 million, a PE ratio of -10.51 and a beta of 1.05. The company has a quick ratio of 3.04, a current ratio of 3.04 and a debt-to-equity ratio of 0.27.

OptimizeRx (NASDAQ:OPRX) last issued its earnings results on Tuesday, April 16th. The company reported $0.11 earnings per share for the quarter. The firm had revenue of $28.37 million for the quarter. OptimizeRx had a negative return on equity of 7.72% and a negative net margin of 24.56%. Analysts forecast that OptimizeRx will post -0.49 earnings per share for the current year.

Hedge Funds Weigh In On OptimizeRx

Institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its stake in shares of OptimizeRx by 215.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,142 shares of the company’s stock worth $31,000 after acquiring an additional 1,462 shares in the last quarter. Cetera Trust Company N.A acquired a new position in shares of OptimizeRx in the 4th quarter valued at approximately $77,000. Quantbot Technologies LP purchased a new position in shares of OptimizeRx during the 3rd quarter valued at approximately $49,000. Tower Research Capital LLC TRC grew its position in shares of OptimizeRx by 407.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,765 shares of the company’s stock worth $97,000 after buying an additional 5,432 shares in the last quarter. Finally, L2 Asset Management LLC bought a new stake in shares of OptimizeRx in the third quarter worth $95,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.